Mimedx and Organogenesis Stocks Tumble After CMS Proposal to Slash Spending
Introduction to CMS Proposal The recent proposal by the Centers for Medicare & Medicaid Services (CMS) has garnered considerable attention due to its implications for the healthcare sector, particularly affecting companies like Mimedx and Organogenesis. This proposal aims to adjust spending on tissue products, which are increasingly scrutinized for their cost-effectiveness within Medicare coverage. By … Read more